Michael L Whitfield

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2807913/publications.pdf

Version: 2024-02-01

80 papers	7,407 citations	81900 39 h-index	82547 72 g-index
83 all docs	83 docs citations	83 times ranked	9078 citing authors

#	Article	IF	Citations
1	Identification of Genes Periodically Expressed in the Human Cell Cycle and Their Expression in Tumors. Molecular Biology of the Cell, 2002, 13, 1977-2000.	2.1	1,352
2	Common markers of proliferation. Nature Reviews Cancer, 2006, 6, 99-106.	28.4	522
3	Systemic and cell type-specific gene expression patterns in scleroderma skin. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12319-12324.	7.1	385
4	Molecular Subsets in the Gene Expression Signatures of Scleroderma Skin. PLoS ONE, 2008, 3, e2696.	2.5	334
5	Shared and distinct mechanisms of fibrosis. Nature Reviews Rheumatology, 2019, 15, 705-730.	8.0	331
6	Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. Journal of Clinical Investigation, 2015, 125, 2795-2807.	8.2	271
7	Myofibroblasts in Murine Cutaneous Fibrosis Originate From Adiponectinâ€Positive Intradermal Progenitors. Arthritis and Rheumatology, 2015, 67, 1062-1073.	5.6	254
8	The Pathogenesis of Systemic Sclerosis. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 509-537.	22.4	247
9	Wnt/Î²â€catenin signaling is hyperactivated in systemic sclerosis and induces Smadâ€dependent fibrotic responses in mesenchymal cells. Arthritis and Rheumatism, 2012, 64, 2734-2745.	6.7	193
10	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>II</scp> Investigatorâ€Initiated, Multicenter, Doubleâ€Blind, Randomized, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	5.6	163
11	PPARÎ³ Downregulation by TGFÃŸ in Fibroblast and Impaired Expression and Function in Systemic Sclerosis: A Novel Mechanism for Progressive Fibrogenesis. PLoS ONE, 2010, 5, e13778.	2.5	158
12	Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. Journal of Investigative Dermatology, 2013, 133, 1979-1989.	0.7	150
13	Universal Reference RNA as a standard for microarray experiments. BMC Genomics, 2004, 5, 20.	2.8	140
14	Intrinsic Gene Expression Subsets of Diffuse Cutaneous Systemic Sclerosis Are Stable in Serial Skin Biopsies. Journal of Investigative Dermatology, 2012, 132, 1363-1373.	0.7	138
15	Limited Systemic Sclerosis Patients with Pulmonary Arterial Hypertension Show Biomarkers of Inflammation and Vascular Injury. PLoS ONE, 2010, 5, e12106.	2.5	133
16	A TGFÎ²-Responsive Gene Signature Is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity. Journal of Investigative Dermatology, 2010, 130, 694-705.	0.7	132
17	Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension. Arthritis and Rheumatism, 2011, 63, 1718-1728.	6.7	125
18	Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis and Rheumatism, 2009, 60, 584-591.	6.7	117

#	Article	IF	Citations
19	Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms. PLoS Computational Biology, 2015, 11, e1004005.	3.2	115
20	Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis. Arthritis Research and Therapy, 2015, 17, 159.	3.5	104
21	Belimumab for the Treatment of Early Diffuse Systemic Sclerosis. Arthritis and Rheumatology, 2018, 70, 308-316.	5.6	98
22	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. Annals of the Rheumatic Diseases, 2020, 79, 379-386.	0.9	97
23	A Longitudinal Biomarker for the Extent of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis and Rheumatology, 2015, 67, 3004-3015.	5.6	95
24	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Medicine, 2017, 9, 27.	8.2	92
25	Nilotinib (Tasignaâ„¢) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Research and Therapy, 2015, 17, 213.	3.5	83
26	Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as a biomarker?. Arthritis Research and Therapy, 2012, 14, R102.	3.5	81
27	Transforming growth factor-beta in systemic sclerosis scleroderma. Frontiers in Bioscience - Scholar, 2009, S1, 226-235.	2.1	79
28	Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. American Journal of Pathology, 2012, 180, 1080-1094.	3.8	78
29	Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placeboâ€Controlled Trial in Adults With Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1350-1360.	5.6	67
30	Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts. PLoS ONE, 2015, 10, e0114017.	2.5	62
31	Postâ€epidemic eosinophiliaâ€“myalgia syndrome associated with Lâ€tryptophan. Arthritis and Rheumatism, 2011, 63, 3633-3639.	6.7	61
32	Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS ONE, 2017, 12, e0187580.	2.5	58
33	Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. JCI Insight, 2016, 1, e89073.	5.0	57
34	A Machine Learning Classifier for Assigning Individual Patients With Systemic Sclerosis to Intrinsic Molecular Subsets. Arthritis and Rheumatology, 2019, 71, 1701-1710.	5.6	56
35	Increased Expression of Endoplasmic Reticulum Stress and Unfolded Protein Response Genes in Peripheral Blood Mononuclear Cells From Patients With Limited Cutaneous Systemic Sclerosis and Pulmonary Arterial Hypertension. Arthritis and Rheumatism, 2013, 65, 1357-1366.	6.7	54
36	Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. Bioinformatics, 2018, 34, 1868-1874.	4.1	53

#	Article	IF	Citations
37	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. Arthritis Research and Therapy, 2015, 17, 194.	3.5	48
38	Antagonistic Effect of the Matricellular Signaling Protein CCN3 on TGF-Î²- and Wnt-Mediated Fibrillinogenesis in Systemic Sclerosis and Marfan Syndrome. Journal of Investigative Dermatology, 2010, 130, 1514-1523.	0.7	47
39	Profibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1160-1169.	5.6	47
40	Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression. Annals of the Rheumatic Diseases, 2016, 75, 303-310.	0.9	45
41	Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. Journal of Investigative Dermatology, 2018, 138, 1301-1310.	0.7	45
42	Egr-1 Induces a Profibrotic Injury/Repair Gene Program Associated with Systemic Sclerosis. PLoS ONE, 2011, 6, e23082.	2.5	42
43	High Rhodotorula Sequences in Skin Transcriptome of Patients with Diffuse Systemic Sclerosis. Journal of Investigative Dermatology, 2014, 134, 2138-2145.	0.7	37
44	Antisense Long Non-Coding RNAs Are Deregulated in Skin Tissue of Patients withÂSystemic Sclerosis. Journal of Investigative Dermatology, 2018, 138, 826-835.	0.7	37
45	Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics. Arthritis and Rheumatology, 2016, 68, 2003-2015.	5.6	35
46	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatology, The, 2020, 2, e743-e753.	3.9	34
47	The Tsk2/+ Mouse Fibrotic Phenotype Is Due to a Gain-of-Function Mutation in the PIIINP Segment of the Col3a1 Gene. Journal of Investigative Dermatology, 2015, 135, 718-727.	0.7	30
48	Machine learning predicts stem cell transplant response in severe scleroderma. Annals of the Rheumatic Diseases, 2020, 79, 1608-1615.	0.9	29
49	Capturing the heterogeneity in systemic sclerosis with genome-wide expression profiling. Expert Review of Clinical Immunology, 2011, 7, 463-473.	3.0	27
50	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	5.6	27
51	Editorial: Plasma and B Cell Gene Signatures: Quantitative Targeting and Monitoring of B Cellâ€“Depleting Therapies in Autoimmune Diseases in the Genomic Era. Arthritis and Rheumatology, 2014, 66, 10-14.	5.6	26
52	Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data. Current Opinion in Rheumatology, 2016, 28, 83-88.	4.3	25
53	Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Research and Therapy, 2019, 21, 49.	3.5	25
54	Gene expression profiling offers insights into the role of innate immune signaling in SSc. Seminars in Immunopathology, 2015, 37, 501-509.	6.1	24

#	Article	IF	Citations
55	A Functional Genomic Meta-Analysis of Clinical Trials in Systemic Sclerosis: TowardÂPrecision Medicine and Combination Therapy. Journal of Investigative Dermatology, 2017, 137, 1033-1041.	0.7	24
56	Systemic Sclerosis Dermal Fibroblasts Induce Cutaneous Fibrosis Through Lysyl Oxidaseâ€“like 4: New Evidence From Threeâ€Dimensional Skinâ€like Tissues. Arthritis and Rheumatology, 2020, 72, 791-801.	5.6	23
57	Lysyl oxidase enzymes mediate TGF-Î²1-induced fibrotic phenotypes in human skin-like tissues. Laboratory Investigation, 2019, 99, 514-527.	3.7	22
58	Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Annals of the Rheumatic Diseases, 2021, 80, 228-237.	0.9	20
59	Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis. Arthritis Research and Therapy, 2016, 18, 27.	3.5	16
60	CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. Scientific Reports, 2020, 10, 6560.	3.3	16
61	Scleroderma gene expression and pathway signatures. Current Rheumatology Reports, 2008, 10, 205-211.	4.7	14
62	Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature. Arthritis Research and Therapy, 2017, 19, 156.	3.5	14
63	The role of Ifng in alterations in liver gene expression in a mouse model of fulminant autoimmune hepatitis. Liver International, 2009, 29, 1307-1315.	3.9	13
64	Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. Journal of Scleroderma and Related Disorders, 2018, 3, 242-248.	1.7	12
65	The Mechanistic Implications of Gene Expression Studies in SSc: Insights From Systems Biology. Current Treatment Options in Rheumatology, 2017, 3, 181-192.	1.4	7
66	Molecular â€œomicâ€•signatures in systemic sclerosis. European Journal of Rheumatology, 2020, 7, 173-180.	0.6	6
67	A case of recalcitrant linear morphea responding to subcutaneous abatacept. Journal of Scleroderma and Related Disorders, 2021, 6, 194-198.	1.7	5
68	Selfâ€Assembled Human Skin Equivalents Model Macrophage Activation of Cutaneous Fibrogenesis in Systemic Sclerosis. Arthritis and Rheumatology, 2022, 74, 1245-1256.	5.6	5
69	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology, 0, , .	1.9	5
70	Clinical and Molecular Findings after Autologous Stem Cell Transplantation or Cyclophosphamide for Scleroderma: Handling Missing Longitudinal Data. Arthritis Care and Research, 2021, , .	3.4	3
71	THU0354â€…MACHINE LEARNING CLASSIFICATION OF SKIN GENE EXPRESSION IDENTIFIES A SUBSET OF SYSTEMIC SCLEROSIS PATIENTS MOST LIKELY TO SHOW CLINICAL IMPROVEMENT IN RESPONSE TO ABATACEPT. , 2019, , .		2
72	Regulator combinations identify systemic sclerosis patients with more severe disease. JCI Insight, 2020, 5, .	5.0	2

#	Article	IF	Citations
73	Mast cell activation in the systemic sclerosis esophagus. Journal of Scleroderma and Related Disorders, 2021, 6, 77-86.	1.7	1
74	Molecular "omic" signatures in systemic sclerosis. European Journal of Rheumatology, 2020, 7, S173-S180.	0.6	1
75	Disease Classification Using Molecular Signatures. , 2012, , 71-81.		0
76	Systems Biology Approaches to Understanding the Pathogenesis of Systemic Sclerosis. , 2017, , 125-129.		0
77	Moving towards a molecular categorization of autoimmune disease. Nature Reviews Rheumatology, 2021, 17, 193-194.	8.0	0
78	Insights Into Systemic Sclerosis from Gene Expression Profiling. Current Treatment Options in Rheumatology, 2021, 7, 208-221.	1.4	0
79	Identification of G1â€Regulated Genes in Normally Cycling Human Cells. FASEB Journal, 2008, 22, 636.4.	0.5	0
80	Molecular Stratification by Gene Expression as a Paradigm for Precision Medicine in Systemic Sclerosis. , 2017, , 657-670.		0